Symbols / FBRX $26.44 +3.36% Forte Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
FBRX Chart
About

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 367.14M
Enterprise Value 278.24M Income -69.38M Sales —
Book/sh 4.71 Cash/sh 5.54 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -6.41 PEG —
P/S — P/B 5.61 P/C —
EV/EBITDA -3.94 EV/Sales — Quick Ratio 3.71
Current Ratio 3.88 Debt/Eq — LT Debt/Eq —
EPS (ttm) -4.71 EPS next Y -4.13 EPS Growth —
Revenue Growth — Earnings 2026-03-31 16:00 ROA -61.19%
ROE -122.28% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 13.89M
Shs Float 7.35M Short Float 6.61% Short Ratio 3.94
Short Interest — 52W High 35.62 52W Low 4.90
Beta — Avg Volume 228.61K Volume 150.51K
Target Price $63.75 Recom Strong_buy Prev Close $25.58
Price $26.44 Change 3.36%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$63.75
Mean price target
2. Current target
$26.44
Latest analyst target
3. DCF / Fair value
$-43.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.44
Low
$54.00
High
$75.00
Mean
$63.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-25 init Evercore ISI Group — → Outperform $65
2025-11-17 main Chardan Capital Buy → Buy $61
2025-08-18 init Guggenheim — → Buy $75
2025-08-15 main Chardan Capital Buy → Buy $61
2025-06-24 main Chardan Capital Buy → Buy $61
2025-04-01 main Chardan Capital Buy → Buy $61
2025-01-21 init TD Cowen — → Buy —
2024-12-04 main Chardan Capital Buy → Buy $64
2024-11-15 main Chardan Capital Buy → Buy $64
2024-08-19 main Chardan Capital Buy → Buy $3
2024-05-30 init Brookline Capital — → Buy $4
2024-04-08 up Ladenburg Thalmann Neutral → Buy $3
2021-09-20 up Chardan Capital Sell → Neutral $4
2021-09-03 down Brookline Capital Buy → Hold —
2021-09-03 down Chardan Capital Buy → Sell $4
2021-09-03 down Ladenburg Thalmann Buy → Neutral —
2021-09-03 down B. Riley Securities Buy → Neutral $3
2021-09-03 down Truist Securities Buy → Hold —
2021-05-14 init B. Riley Securities — → Buy $73
2021-03-26 init Citigroup — → Buy $75
News
RSS: Latest FBRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-31 RILEY ANTONY A Chief Financial Officer — 375 — —
2025-12-31 WAGNER PAUL A Chief Executive Officer — 1,250 — —
2025-12-30 RILEY ANTONY A Chief Financial Officer — 9,680 $26.33 $254,833
2025-10-01 RILEY ANTONY A Chief Financial Officer — 375 — —
2025-10-01 WAGNER PAUL A Chief Executive Officer — 1,250 — —
2025-07-01 RILEY ANTONY A Chief Financial Officer — 375 — —
2025-07-01 WAGNER PAUL A Chief Executive Officer — 1,250 — —
2025-04-01 RILEY ANTONY A Chief Financial Officer — 375 — —
2025-04-01 WAGNER PAUL A Chief Executive Officer — 1,250 — —
2024-12-31 RILEY ANTONY A Chief Financial Officer — 375 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
70.66
+93.04%
36.60
+12.67%
32.49
+133.78%
13.90
Research And Development
58.25
+174.84%
21.19
-3.06%
21.86
+290.81%
5.59
Selling General And Administration
12.41
-19.46%
15.41
+45.04%
10.62
+27.97%
8.30
General And Administrative Expense
12.41
-19.46%
15.41
+45.04%
10.62
+27.97%
8.30
Other Gand A
12.41
-19.46%
15.41
+45.04%
10.62
+27.97%
8.30
Total Expenses
70.66
+93.04%
36.60
+12.67%
32.49
+133.78%
13.90
Operating Income
-70.66
-93.04%
-36.60
-12.67%
-32.49
-133.78%
-13.90
Total Operating Income As Reported
-70.66
-93.04%
-36.60
-12.67%
-32.49
-133.78%
-13.90
EBITDA
-70.59
-93.07%
-36.56
-12.58%
-32.48
-133.71%
-13.90
Normalized EBITDA
-70.59
-93.07%
-36.56
-12.58%
-32.48
-133.71%
-13.90
Reconciled Depreciation
0.06
+64.10%
0.04
+333.33%
0.01
0.00
EBIT
-70.66
-93.04%
-36.60
-12.67%
-32.49
-133.78%
-13.90
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Net Income
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Pretax Income
-68.34
-92.62%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Net Non Operating Interest Income Expense
2.71
+106.62%
1.31
+16.90%
1.12
+593.83%
0.16
Net Interest Income
2.71
+106.62%
1.31
+16.90%
1.12
+593.83%
0.16
Interest Income Non Operating
2.71
+106.62%
1.31
+16.90%
1.12
+593.83%
0.16
Interest Income
2.71
+106.62%
1.31
+16.90%
1.12
+593.83%
0.16
Other Income Expense
-0.40
-108.42%
-0.19
-66.67%
-0.11
+21.38%
-0.14
Other Non Operating Income Expenses
-0.40
-108.42%
-0.19
-66.67%
-0.11
+21.38%
-0.14
Tax Provision
1.04
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Net Income From Continuing Operation Net Minority Interest
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Net Income From Continuing And Discontinued Operation
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Net Income Continuous Operations
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Normalized Income
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Net Income Common Stockholders
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Diluted EPS
-4.71
+61.30%
-12.17
+51.16%
-24.92
-24.60%
-20.00
Basic EPS
-4.71
+61.30%
-12.17
+51.16%
-24.92
-24.60%
-20.00
Basic Average Shares
14.72
+404.74%
2.92
+130.90%
1.26
+81.61%
0.70
Diluted Average Shares
14.72
+404.74%
2.92
+130.90%
1.26
+81.61%
0.70
Diluted NI Availto Com Stockholders
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Line Item Trend 2023-12-31
Total Assets
38.98
Current Assets
38.33
Cash Cash Equivalents And Short Term Investments
37.12
Cash And Cash Equivalents
11.96
Cash Equivalents
5.69
Cash Financial
6.28
Other Short Term Investments
25.16
Receivables
—
Taxes Receivable
—
Prepaid Assets
1.04
Other Current Assets
0.17
Total Non Current Assets
0.65
Net PPE
0.11
Gross PPE
0.12
Accumulated Depreciation
-0.01
Machinery Furniture Equipment
0.02
Other Properties
0.10
Non Current Prepaid Assets
0.49
Other Non Current Assets
0.05
Total Liabilities Net Minority Interest
3.67
Current Liabilities
3.67
Payables And Accrued Expenses
2.72
Payables
1.42
Accounts Payable
1.42
Current Accrued Expenses
1.29
Pensionand Other Post Retirement Benefit Plans Current
0.95
Total Non Current Liabilities Net Minority Interest
0.00
Tradeand Other Payables Non Current
—
Preferred Securities Outside Stock Equity
—
Stockholders Equity
35.31
Common Stock Equity
35.31
Capital Stock
0.00
Common Stock
0.00
Share Issued
1.45
Ordinary Shares Number
1.45
Treasury Shares Number
0.00
Additional Paid In Capital
153.83
Retained Earnings
-118.52
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
0.00
Total Equity Gross Minority Interest
35.31
Total Capitalization
35.31
Working Capital
34.66
Invested Capital
35.31
Net Tangible Assets
35.31
Tangible Book Value
35.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-50.88
-65.50%
-30.75
-7.10%
-28.71
-250.71%
-8.19
Cash Flow From Continuing Operating Activities
-50.88
-65.50%
-30.75
-7.10%
-28.71
-250.71%
-8.19
Net Income From Continuing Operations
-69.38
-95.54%
-35.48
-12.71%
-31.48
-126.79%
-13.88
Depreciation Amortization Depletion
0.06
+64.10%
0.04
+333.33%
0.01
0.00
Depreciation
0.06
+64.10%
0.04
+333.33%
0.01
0.00
Depreciation And Amortization
0.06
+64.10%
0.04
+333.33%
0.01
0.00
Other Non Cash Items
-0.24
-50.00%
-0.16
-20.61%
-0.13
—
Stock Based Compensation
6.26
+102.20%
3.10
-5.76%
3.28
-18.21%
4.01
Asset Impairment Charge
—
—
—
0.00
Deferred Tax
1.04
0.00
—
—
Deferred Income Tax
1.04
0.00
—
—
Change In Working Capital
11.37
+547.18%
1.76
+548.21%
-0.39
-123.35%
1.68
Change In Prepaid Assets
-2.57
-87.47%
-1.37
-61.72%
-0.85
-429.07%
0.26
Change In Payables And Accrued Expense
13.95
+345.53%
3.13
+584.90%
0.46
-67.84%
1.42
Change In Accrued Expense
8.40
+7608.26%
0.11
-41.40%
0.19
-84.68%
1.21
Change In Payable
5.54
+83.48%
3.02
+1014.76%
0.27
+30.92%
0.21
Change In Account Payable
5.54
+83.48%
3.02
+1014.76%
0.27
+30.92%
0.21
Investing Cash Flow
36.23
+200.67%
-35.99
-76680.85%
0.05
0.00
Cash Flow From Continuing Investing Activities
36.23
+200.67%
-35.99
-76680.85%
0.05
0.00
Net PPE Purchase And Sale
-0.12
-213.51%
-0.04
+57.95%
-0.09
0.00
Purchase Of PPE
-0.12
-213.51%
-0.04
+57.95%
-0.09
0.00
Capital Expenditure
-0.12
-213.51%
-0.04
+57.95%
-0.09
—
Net Investment Purchase And Sale
36.35
+201.10%
-35.96
-26734.07%
0.14
0.00
Purchase Of Investment
0.00
+100.00%
-35.96
-260.82%
-9.96
0.00
Sale Of Investment
36.35
0.00
-100.00%
10.10
0.00
Financing Cash Flow
69.36
+33.75%
51.86
+110.08%
24.68
+240.89%
7.24
Cash Flow From Continuing Financing Activities
69.36
+33.75%
51.86
+110.08%
24.68
+240.89%
7.24
Net Common Stock Issuance
75.00
+41.51%
53.00
+112.00%
25.00
+245.83%
7.23
Common Stock Payments
0.00
+100.00%
-0.00
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.00
0.00
—
Proceeds From Stock Option Exercised
1.83
+12978.57%
0.01
-12.50%
0.02
+33.33%
0.01
Net Other Financing Charges
-7.47
-546.19%
-1.16
-248.19%
-0.33
—
Changes In Cash
54.71
+467.67%
-14.88
-274.36%
-3.98
-321.08%
-0.94
Beginning Cash Position
22.24
-40.08%
37.12
-9.67%
41.10
-2.25%
42.04
End Cash Position
76.96
+245.97%
22.24
-40.08%
37.12
-9.67%
41.10
Free Cash Flow
-51.00
-65.67%
-30.78
-6.90%
-28.79
-251.79%
-8.19
Common Stock Issuance
75.00
+41.51%
53.00
+112.00%
25.00
+245.83%
7.23
Issuance Of Capital Stock
75.00
+41.51%
53.00
+112.00%
25.00
+245.83%
7.23
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category